MECOM and renal cell carcinoma: Strikingly, as showed in Table 2, seven HMTs (NSD1, PRDM6, MECOM, KMT2C, EZH2, PRDM14, and KMT2E) exhibited high-level amplification in more than 0.5% of RCC samples, and two of these seven HMTs (NSD1 and PRDM6) had a much higher amplification rate in over 10% of ccRCC samples.